188 related articles for article (PubMed ID: 24236111)
1. Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells.
Barboro P; Borzì L; Repaci E; Ferrari N; Balbi C
PLoS One; 2013; 8(11):e79212. PubMed ID: 24236111
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.
Barboro P; Salvi S; Rubagotti A; Boccardo S; Spina B; Truini M; Carmignani G; Introini C; Ferrari N; Boccardo F; Balbi C
Int J Oncol; 2014 May; 44(5):1589-98. PubMed ID: 24626777
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.
Barboro P; Repaci E; Ferrari N; Rubagotti A; Boccardo F; Balbi C
Prostate; 2011 Sep; 71(13):1466-79. PubMed ID: 21321982
[TBL] [Abstract][Full Text] [Related]
4. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation.
Mukhopadhyay NK; Kim J; Cinar B; Ramachandran A; Hager MH; Di Vizio D; Adam RM; Rubin MA; Raychaudhuri P; De Benedetti A; Freeman MR
Cancer Res; 2009 Mar; 69(6):2210-8. PubMed ID: 19258514
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.
Barboro P; Repaci E; Rubagotti A; Salvi S; Boccardo S; Spina B; Truini M; Introini C; Puppo P; Ferrari N; Carmignani G; Boccardo F; Balbi C
Br J Cancer; 2009 May; 100(10):1608-16. PubMed ID: 19401687
[TBL] [Abstract][Full Text] [Related]
8. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
Berrevoets CA; Umar A; Trapman J; Brinkmann AO
Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
[TBL] [Abstract][Full Text] [Related]
9. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
[TBL] [Abstract][Full Text] [Related]
10. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
[TBL] [Abstract][Full Text] [Related]
12. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
13. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
14. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
[TBL] [Abstract][Full Text] [Related]
15. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
16. Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54.
Yang Z; Chang YJ; Miyamoto H; Yeh S; Yao JL; di Sant'Agnese PA; Tsai MY; Chang C
Endocrinology; 2007 Mar; 148(3):1340-9. PubMed ID: 17110431
[TBL] [Abstract][Full Text] [Related]
17. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line.
Paris F; Rabeolina F; Balaguer P; Bacquet A; Sultan C
Gynecol Endocrinol; 2007 Apr; 23(4):193-7. PubMed ID: 17505938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
